OssDsign was awarded a new group purchasing agreement for Bone and Bone Substitute Implantable Products with Premier, a U.S. healthcare improvement company representing an alliance of approximately 4,350 U.S. hospitals and health systems and more than 300,000 other providers and organizations. The agreement is for a period of three years.
The agreement allows Premier members to take advantage of special pricing and terms pre-negotiated by Premier for OssDsign’s nanosynthetic bone graft OssDsign Catalyst.
OssDsign Catalyst is designed to stimulate the formation of healthy bone tissue in spinal fusion. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue in the body. Twelve-month results from the TOP FUSION clinical study show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with OssDsign Catalyst.
“We are very pleased to have been awarded a long-term agreement with Premier for our innovative synthetic bone graft. It is a clear recognition of our market offering, and opens up a large, valuable network providing many more hospitals and patients access to OssDsign Catalyst,” said Morten Henneveld, CEO, OssDsign.
OssDsign was awarded a new group purchasing agreement for Bone and Bone Substitute Implantable Products with Premier, a U.S. healthcare improvement company representing an alliance of approximately 4,350 U.S. hospitals and health systems and more than 300,000 other providers and organizations. The agreement is for a period of three years.
The...
OssDsign was awarded a new group purchasing agreement for Bone and Bone Substitute Implantable Products with Premier, a U.S. healthcare improvement company representing an alliance of approximately 4,350 U.S. hospitals and health systems and more than 300,000 other providers and organizations. The agreement is for a period of three years.
The agreement allows Premier members to take advantage of special pricing and terms pre-negotiated by Premier for OssDsign’s nanosynthetic bone graft OssDsign Catalyst.
OssDsign Catalyst is designed to stimulate the formation of healthy bone tissue in spinal fusion. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue in the body. Twelve-month results from the TOP FUSION clinical study show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with OssDsign Catalyst.
“We are very pleased to have been awarded a long-term agreement with Premier for our innovative synthetic bone graft. It is a clear recognition of our market offering, and opens up a large, valuable network providing many more hospitals and patients access to OssDsign Catalyst,” said Morten Henneveld, CEO, OssDsign.
Copy to clipboard 
